≥96% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Protected from light,Argon charged,Desiccated,Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways
In Vitro
DA-JC4 (1~100 nM; hippocampal cells) inhibits rotenone-induced hippocampal neuron death and significantly suppresses Cyt C, Bax and Caspase activation. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
DA-JC4 (10 nmol/kg; i.p.; once-daily for 14 days) significantly prevents spatial learning deficits in a Y- maze test and Morris water maze tests, and decreases phosphorylated tau levels in the rat cerebral cortex and hippocampus . DA-JC4 (25 nmol/kg; i.p.; 6 days) shows high levels expression of tyrosine Hydroxylase in the s. nigra and increases expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF). DA-JC4 (50 nmol/kg; i.p.; once-daily for 7 days) improves Parkinson's disease symptom potentially and enhances neurotransmission. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley rats (210–230 g) Dosage: 10 nmol/kg Administration: I.p. Result: Significantly prevented spatial learning deficits in a Y- maze test and Morris water maze tests, and decreased phosphorylated tau levels in the rat cerebral cortex and hippocampus. Animal Model: Adult male C57BL/6 mice (8 week-old) Dosage: 25 nmol/kg/day Administration: I.p. Result: Showed high levels expression of tyrosine Hydroxylase in the s. nigra and increased expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF). Animal Model: Adult male Sprague-Dawley (SD) rats (230-280 g) Dosage: 50 nmol/kg Administration: I.p. Result: Improved Parkinson's disease symptom potentially and enhanced neurotransmission.
Form:Solid
IC50& Target:GLP-1/GIP
| Peso molecular | 4875.49 |
|---|
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →
